US reports a record number of new coronavirus disease 2019 (COVID-19) cases; FDA reviewers endorse an Alzheimer disease drug; CDC director calls for asymptomatic testing strategy.
For the first time, the United States has reported 100,000 new coronavirus disease 2019 (COVID-19) cases in a single day, The New York Times reports. Ten months into the global pandemic, the new surge in cases has led to a shortage of N95 face masks at many health care facilities, despite increased production, according to The Wall Street Journal. Although the national supply of personal protective equipment (PPE) has improved since the spring, levels at some facilities remain below regulator-recommended levels. Because of the shortage, workers continue to ration and reuse masks, and state health departments warn that supplies may tighten further. In Michigan, almost two-thirds of health systems report less than a 3-week supply for 1 or more types of protective gear.
FDA clinical reviewers said that data showing that a new treatment for Alzheimer disease slowed cognitive decline were “exceptionally persuasive,” The Washington Post reports. The treatment, called aducanumab and developed by Biogen, appears to be safe and effective for treating patients with early-stage disease. Outside experts will now decide whether to recommend the agency approves the drug, making it the first new treatment for Alzheimer disease in nearly 2 decades. However, conflicting evidence on the drug’s effectiveness has led to controversy around the treatment, with one study concluding it was effective and another stating it showed little benefit. An FDA announcement on approval is expected by early March 2021.
CDC Director Robert Redfield, MD, stated that now is the time to develop a testing strategy for asymptomatic cases of COVID-19, CNN reports. CDC estimates show that 40% of individuals with COVID-19 show no symptoms. The announcement comes after a meeting with fellow White House Coronavirus Task Force member Deborah Birx, MD, and Utah Governor Gary Herbert to discuss mitigation efforts and testing in Utah. However, some experts feel the time to develop a testing strategy for this population has already passed. Currently, hospitalizations for COVID-19 are steeply rising in the Midwest, while nationwide, hospitalizations have increased 76% since September.
Early Involvement Critical in Treating Immunotherapy-Induced Overlap Syndrome
April 19th 2024A series of case studies reveals the importance of early diagnosis and involvement of special teams of clinicians when dealing with potential cases of overlap syndrome, which encompasses myocarditis, myasthenia gravis, and immune checkpoint inhibitor–related myositis.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Real-World Study Reveals Key Insights Into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More